biote Corp. reported second quarter 2026 financial results on August 5, 2026, revealing a net loss of $7.4 million and diluted loss per share of $0.23, compared to net income of $3.9 million in the prior year period. Total revenue declined 9.5% to $44.2 million, driven by a 13.9% drop in procedure revenue to $30.3 million due to a voluntary product recall initiated in January 2026 involving hormone pellets from supplier Asteria Health. Gross profit margin contracted to 65.4% from 71.6%, while Adjusted EBITDA fell to $5.6 million from $15.2 million. The company revised its full-year guidance, projecting revenue above $175 million and Adjusted EBITDA above $25 million, noting that procedure revenue is expected to improve sequentially but remain below year-over-year levels due to the recall disruption. biote Corp. operates in the hormone optimization and healthy aging solutions industry.

biote Corp. announced an amended and restated employment agreement for Interim CEO Robert Peterson, effective June 12, 2026. The agreement includes an annual base salary of $658,800, an annual incentive compensation eligibility of up to 72.5% of base salary, and stock option awards representing 0.56% of outstanding shares. biote Corp. is a medical technology company that provides biological and biological-based solutions for wellness and wellness-based products.